{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.5","value":"211"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.8","value":"717"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Treatment - week 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","title":"Maximum Concentration (Cmax) of Alectinib","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter (ng/mL)"}